arrow
B

Bogusława Karaszewska

université psl
H指数:26
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
2022-01-10128
OA
KEYNOTE-042 5-YEAR SURVIVAL UPDATE: PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, PD-L1POSITIVE, LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
2021-11-108
OA
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
2021-06-096
OAAI
Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
2021-03-2115
OAAI
Results of a phase II double-blinded, randomized, placebo-controlled clinical trial of Indoximod, an Indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor, in combination with Taxane chemotherapy in metastatic breast cancer (MBC)
2020-02-150
PRE
Subcutaneous trastuzumab and hyaluronidase-oysk with intravenous pertuzumab and docetaxel in HER2-positive advanced breast cancer: Final analysis of the phase IIIb, multicenter, open-label, single-arm MetaPHER study
2020-02-150
PRE
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

Dabrafenib联合曲美替尼治疗转移性黑色素瘤的五年预后

2019-08-15954
OAAI
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
2017-09-01148
PREAI
Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) plus trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma
2016-10-0134
OAAI
COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D plus T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM)
2015-09-010
PREAI
Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
2015-09-0142
PREAI
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

达拉非尼和曲美替尼联合改善黑色素瘤的总生存率

2015-01-012.2K
OAAI
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
LANCET
IF88.5
2012-07-012.6K
PREAI